I think there is a miscomprehension here. There are no returns...

I think there is a miscomprehension here.
There are no returns to investors in an R&D Biotech until it has a commercial product, ie, a product/s that sells, that makes a profit.
It is impossible to create a return or dividend until this happens unless there is a profitable sale, of something like a license or ownership buyout. But they would still rely on a marketable product.
To state the obvious, we don't have a marketable product, YET.
So there is no return, no dividend, and no reasonable person can expect one yet.
We know that the time for success or failure of a marketable product is most likely mid-2024, so expecting anything before that is very very highly unlikely unless something like an ATL-1103 licensing deal came about or a Covid deal came about. But unlikely before 2024 June.
In the meantime, we are at the whims of the market and its forces, and unfortunately, that includes large institutional owners of ANP.PER selling off to rebalance or secure profits in their investment, into a low volatility thinly traded market, hence how easily the share price drops, but the converse can also occur just as quickly if the right situation presents itself.
It doesn't matter if it is Diamond or Garner or Charmain you cant always stimulate a share price that has no commercial product, no income, at all, and even if you can it will likely be temporary as the market dictates after short rises individuals or groups will take advantage of said rise and take profits, therefore bringing the price back down.
There is no magic button.

In an R&D Biotech, still developing, the value a CEO or company provides is more often than not, the value of staying solvent, the value of researching viable products, the value of developing said products, and the value of bringing one or more products to commercialisation.
It would be a miscomprehension to think that bringing value to a shareholder in an R&D biotech that has no value, is by an ever-increasing share price.
That would be an exception by a fad or fresh trend where wild speculation can create long runs up, but virtually none can sustain, what sustains is sales revenue that makes good profits.
Thats reality.